Article: Geron Receives U.S. Patent for Human Telomerase Promoter Triggering Milestone Payment.

Business Editors/Health/Medical Writers

MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 26, 2003

Geron Corporation (Nasdaq:GERN) announced today that it has been granted U.S. Patent No. 6,610,839, by the U.S. Patent and Trademark Office, with claims covering the promoter that regulates expression of the human telomerase reverse transcriptase gene (the "hTERT promoter"). Geron had non-exclusively licensed the hTERT promoter to Genetic Therapy, Inc. ("GTI"), a subsidiary of Novartis AG, for use in the development of viruses that are designed to target cancer cells. Cell Genesys, Inc. (Nasdaq:CEGE) recently acquired rights to the GTI product portfolio and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!